Ketorolac Pensa

Ketorolac Trometamol, the active ingredient in Ketorolac Pensa, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral formulation for systemic use. It is indicated for short‑term treatment of moderate to severe pain, including post‑operative pain, in adult patients. GNH USA supplies Ketorolac Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketorolac Pensa is an NSAID that provides analgesia by reducing prostaglandin‑mediated inflammation. - Moderate to severe acute pain: delivers short‑term analgesic relief when non‑opioid therapy is needed. - Post‑operative pain: helps control pain following surgical procedures. - Musculoskeletal pain: alleviates pain associated with injuries or strain.

Ketorolac Pensa may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Dyspepsia or stomach upset - Headache - Dizziness - Abdominal pain - Diarrhoea

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulceration - Acute renal impairment or failure - Severe allergic reactions (e.g., anaphylaxis, Stevens‑Johnson syndrome) - Cardiovascular events such as myocardial infarction or stroke - Hepatotoxicity - Thrombocytopenia or other blood dyscrasias

Before prescribing Ketorolac Pensa, clinicians should consider several safety measures. - Assess renal function: evaluate baseline kidney status and avoid use in severe impairment. - Avoid in active peptic ulcer disease: heightened risk of gastrointestinal bleeding. - Limit duration: restrict therapy to the shortest effective period, typically not exceeding five days. - Monitor cardiovascular risk: use cautiously in patients with history of heart disease or stroke. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ketorolac Pensa can interact with other medicines, requiring careful review.

Major Interactions (Avoid): - Concurrent NSAIDs: additive risk of gastrointestinal bleeding and ulceration. - Anticoagulants (e.g., warfarin, DOACs): increased bleeding tendency. - SSRIs or SNRIs: enhanced risk of hemorrhagic events.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal perfusion, especially in volume‑depleted patients. - Diuretics: combined use can precipitate renal dysfunction. - Lithium: NSAIDs can raise lithium serum concentrations, necessitating level monitoring.